Disclaimer:

Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.

GlucaGen

&times

Overview

What is GlucaGen?

GlucaGen (glucagon) for injection is an antihypoglycemic agent and a gastrointestinal motility inhibitor for subcutaneous, intramuscular or intravenous use. It is produced by expression of recombinant DNA in a vector with subsequent purification. The chemical structure of the glucagon in GlucaGen is identical to human glucagon and to glucagon extracted from beef and pork pancreas. Glucagon with the empirical formula of CHNOS, and a molecular weight of 3483, is a single-chain polypeptide containing 29 amino acid residues. The structure of glucagon is:

GlucaGen is a sterile, lyophilized white powder in a 2 mL vial (appearance of the powder may vary, and occasionally the powder may appear compacted). The reconstituted solution contains glucagon as hydrochloride 1 mg/mL and lactose monohydrate (107 mg). GlucaGen is supplied at pH 2.5-3.5 and is soluble in water.



What does GlucaGen look like?



What are the available doses of GlucaGen?

GlucaGen is supplied in a vial, alone, or accompanied by Sterile Water for Reconstitution (1 mL) also in a vial (10 pack or diagnostic kit). It is also supplied as GlucaGen HypoKit, a presentation with a disposable prefilled syringe containing 1 mL Sterile Water for Reconstitution. When the glucagon powder is reconstituted with Sterile Water for Reconstitution (if supplied) or with Sterile Water for Injection, USP, it forms a solution of 1 mg/mL glucagon for subcutaneous, intramuscular, or intravenous injection (appearance of the powder may vary, and occasionally the powder may appear compacted).

What should I talk to my health care provider before I take GlucaGen?

How should I use GlucaGen?

GlucaGen is used to treat severe hypoglycemic (low blood sugar) reactions which may occur in patients with diabetes mellitus treated with insulin. Because GlucaGen depletes glycogen stores, the patient should be given supplemental carbohydrates as soon as he/she awakens and is able to swallow, especially children or adolescents. Medical evaluation is recommended for all patients who experience severe hypoglycemia.

For GlucaGen HypoKit:


What interacts with GlucaGen?

Sorry No Records found


What are the warnings of GlucaGen?

Sorry No Records found


What are the precautions of GlucaGen?

Sorry No Records found


What are the side effects of GlucaGen?

Sorry No records found


What should I look out for while using GlucaGen?

GlucaGen is contraindicated in patients with:


What might happen if I take too much GlucaGen?

No reports of overdosage with GlucaGen have been reported. If overdosage occurs, the patient may experience nausea, vomiting, inhibition of GI tract motility, increase in blood pressure and pulse rate. In case of suspected overdosing, the serum potassium may decrease and should be monitored and corrected if needed. If the patient develops a dramatic increase in blood pressure, phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.


How should I store and handle GlucaGen?

Divalproex sodiumextended-release tablets USP, 500mg are available as grey colored, oval shaped, beveled edge, biconvex coated tablets debossed “R” on one side and “534” on other side. Each divalproex sodium extended-release tablet contains divalproex sodiumequivalent to 500 mg of valproic acid and are supplied in bottles of 30’s, 60’s, 100’s and 500’s. Bottles of 30 NDC 55111-534-30 Bottles of 60 NDC 55111-534-60 Bottles of 100 NDC 55111-534-01 Bottles of 500 NDC 55111-534-05Recommended StorageStore tablets at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Divalproex sodiumextended-release tablets USP, 500mg are available as grey colored, oval shaped, beveled edge, biconvex coated tablets debossed “R” on one side and “534” on other side. Each divalproex sodium extended-release tablet contains divalproex sodiumequivalent to 500 mg of valproic acid and are supplied in bottles of 30’s, 60’s, 100’s and 500’s. Bottles of 30 NDC 55111-534-30 Bottles of 60 NDC 55111-534-60 Bottles of 100 NDC 55111-534-01 Bottles of 500 NDC 55111-534-05Recommended StorageStore tablets at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Divalproex sodiumextended-release tablets USP, 500mg are available as grey colored, oval shaped, beveled edge, biconvex coated tablets debossed “R” on one side and “534” on other side. Each divalproex sodium extended-release tablet contains divalproex sodiumequivalent to 500 mg of valproic acid and are supplied in bottles of 30’s, 60’s, 100’s and 500’s. Bottles of 30 NDC 55111-534-30 Bottles of 60 NDC 55111-534-60 Bottles of 100 NDC 55111-534-01 Bottles of 500 NDC 55111-534-05Recommended StorageStore tablets at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Divalproex sodiumextended-release tablets USP, 500mg are available as grey colored, oval shaped, beveled edge, biconvex coated tablets debossed “R” on one side and “534” on other side. Each divalproex sodium extended-release tablet contains divalproex sodiumequivalent to 500 mg of valproic acid and are supplied in bottles of 30’s, 60’s, 100’s and 500’s. Bottles of 30 NDC 55111-534-30 Bottles of 60 NDC 55111-534-60 Bottles of 100 NDC 55111-534-01 Bottles of 500 NDC 55111-534-05Recommended StorageStore tablets at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Divalproex sodiumextended-release tablets USP, 500mg are available as grey colored, oval shaped, beveled edge, biconvex coated tablets debossed “R” on one side and “534” on other side. Each divalproex sodium extended-release tablet contains divalproex sodiumequivalent to 500 mg of valproic acid and are supplied in bottles of 30’s, 60’s, 100’s and 500’s. Bottles of 30 NDC 55111-534-30 Bottles of 60 NDC 55111-534-60 Bottles of 100 NDC 55111-534-01 Bottles of 500 NDC 55111-534-05Recommended StorageStore tablets at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Divalproex sodiumextended-release tablets USP, 500mg are available as grey colored, oval shaped, beveled edge, biconvex coated tablets debossed “R” on one side and “534” on other side. Each divalproex sodium extended-release tablet contains divalproex sodiumequivalent to 500 mg of valproic acid and are supplied in bottles of 30’s, 60’s, 100’s and 500’s. Bottles of 30 NDC 55111-534-30 Bottles of 60 NDC 55111-534-60 Bottles of 100 NDC 55111-534-01 Bottles of 500 NDC 55111-534-05Recommended StorageStore tablets at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature]. Divalproex sodiumextended-release tablets USP, 500mg are available as grey colored, oval shaped, beveled edge, biconvex coated tablets debossed “R” on one side and “534” on other side. Each divalproex sodium extended-release tablet contains divalproex sodiumequivalent to 500 mg of valproic acid and are supplied in bottles of 30’s, 60’s, 100’s and 500’s. Bottles of 30 NDC 55111-534-30 Bottles of 60 NDC 55111-534-60 Bottles of 100 NDC 55111-534-01 Bottles of 500 NDC 55111-534-05Recommended StorageStore tablets at 20°-25°C (68°-77°F) [See USP Controlled Room Temperature].


&times

Clinical Information

Chemical Structure

No Image found
Clinical Pharmacology

Antihypoglycemic Action:

Gastrointestinal Motility Inhibition:

Non-Clinical Toxicology
GlucaGen is contraindicated in patients with:

GlucaGen is contraindicated in patients with pheochromocytoma because GlucaGen may stimulate the release of catecholamines from the tumor. If the patient develops a dramatic increase in blood pressure, 5 to 10 mg of phentolamine mesylate has been shown to be effective in lowering blood pressure for the short time that control would be needed.

Side effects may include nausea and vomiting at doses above 1 mg or with rapid injection. Hypotension has been reported up to 2 hours after administration in patients receiving GlucaGen as premedication for upper GI endoscopy procedures. GlucaGen exerts positive inotropic and chronotropic effects and may, therefore, cause tachycardia and hypertension. Adverse reactions indicating toxicity of GlucaGen have not been reported. A temporary increase in both blood pressure and pulse rate may occur following the administration of GlucaGen. Patients taking beta-blockers might be expected to have a greater increase in both pulse and blood pressure, an increase of which will be temporary because of GlucaGen’s short half-life . The increase in blood pressure and pulse rate may require therapy in patients with pheochromocytoma or coronary artery disease Anaphylactic reactions may occur in some cases .

The following adverse reactions have been identified during postapproval use of GlucaGen. Because these reactions are reported voluntarily from a population of uncertain size, it is generally not possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

&times

Reference

This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"

While we update our database periodically, we cannot guarantee it is always updated to the latest version.

&times

Review

Rate this treatment and share your opinion


Helpful tips to write a good review:

  1. Only share your first hand experience as a consumer or a care giver.
  2. Describe your experience in the Comments area including the benefits, side effects and how it has worked for you. Do not provide personal information like email addresses or telephone numbers.
  3. Fill in the optional information to help other users benefit from your review.

Reason for Taking This Treatment

(required)

Click the stars to rate this treatment

This medication has worked for me.




This medication has been easy for me to use.




Overall, I have been satisfied with my experience.




Write a brief description of your experience with this treatment:

2000 characters remaining

Optional Information

Help others benefit from your review by filling in the information below.
I am a:
Gender:
&times

Professional

Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72
&times

Tips

Tips

&times

Interactions

Interactions

A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).